Correction {#Sec1}
==========

The original article \[1\] contains a number of statements that the authors would like to be disregarded, noted ahead:In the Methods section, along with the references mentioned in the statement:"'In order to account for the effect of medication behavior, the Morisky 8-item medication adherence scale (MMAS-8) \[30\] was applied to measure medication adherence. The MMAS-8 is one of the most commonly used self-report adherence questionnaires. The Chinese version of MMAS-8 has been validated among a convenience sample of 176 patients in China \[31\]. The scale showed acceptable internal consistency (Cronbach's α = 0.77) and test-retest reliability (r = 0.88), and good construct validity.'"In the respective captions of Tables 3 and 4:"'The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale'."Table 3Mixed effect model analysis of metformin effect on general HRQoL outcome measured via WHOQOL-BrefWHOQOL-BrefTotal\
Coefficient (SE)SubgroupsNormal weight\
Coefficient (SE)Overweight\
Coefficient (SE)Non- hyperandrogenism\
Coefficient (SE)Hyperandrogenism\
Coefficient (SE)Total scores Treatment time  Visit 2 (reference = visit 1)−0.93 (1.04)0.47 (0.77)−1.72 (1.44)1.49 (1.26)0.79 (0.56)  Visit 3 (reference = visit 1)0.06 (0.94)0.07 (0.75)−0.27 (1.45)0.52 (1.30)0.70 (0.56)Physical domain Treatment time*p = 0.010p = 0.036p = 0.015*  Visit 2 (reference = visit 1)0.58 (0.20)\*0.50 (0.29)0.57 (0.28)\*0.62 (0.50)0.55 (0.22)\*  Visit 3 (reference = visit 1)0.54 (0.20)\*0.50 (0.29)0.64 (0.27)\*0.29 (0.51)0.60 (0.22)\*Psychological domain Treatment time  Visit 2 (reference = visit 1)−0.90 (0.06)−0.17 (0.34)−1.49 (0.57)0.63 (0.58)−0.16 (0.23)  Visit 3 (reference = visit 1)−0.06 (0.39)−0.14 (0.33)−0.76 (0.57)0.17 (0.60)0.002 (0.23)Social domain Treatment time  Visit 2 (reference = visit 1)−0.61 (0.39)0.10 (0.31)0.18 (0.24)−0.83 (0.69)0.05 (0.21)  Visit 3 (reference = visit 1)−0.31 (0.35)−0.31 (0.30)0.14 (0.25)−0.02 (0.63)−0.14 (0.21)Environment domain Treatment time  Visit 2 (reference = visit 1)0.13 (0.15)−0.07 (0.23)0.29 (0.21)−0.34 (0.27)0.23 (0.18)  Visit 3 (reference = visit 1)0.07 (0.16)−0.06 (0.22)0.17 (0.22)−0.16 (0.28)0.10 (0.18)Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). Once PCOS was diagnosed, patients started metformin treatment. Visit 2 was 2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th month of treatment). The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale*Abbreviations*: *HRQoL* health-related quality of life, *SE* standard error\**p* \< 0.05Table 4Mixed effect model analysis of metformin effect on PCOS-specific HRQoL measured via Chi-PCOSQChi-PCOSQTotal\
Coefficient (SE)SubgroupsNormal weight\
Coefficient (SE)Overweight\
Coefficient (SE)Non- hyperandrogenism\
Coefficient (SE)Hyperandrogenism\
Coefficient (SE)Total scores Treatment time  Visit 2 (reference = visit 1)0.44 (0.56)0.75 (0.86)0.20 (0.75)−0.58 (0.89)0.61 (0.66)  Visit 3 (reference = visit 1)1.25 (0.56)1.77 (0.84)0.80 (0.78)0.11 (0.92)1.45 (0.66)\*Weight domain Treatment time  Visit 2 (reference = visit 1)−0.06 (0.14)0.11 (0.22)−0.18 (0.19)−0.04 (0.28)−0.07 (0.17)  Visit 3 (reference = visit 1)0.12 (0.15)0.15 (0.21)0.10 (0.20)−0.01 (0.29)0.15 (0.17)Infertility domain Treatment time*p = 0.043p = 0.048*  Visit 2 (reference = visit 1)0.25 (0.18)0.34 (0.23)0.15 (0.29)−0.06 (0.33)0.32 (0.21)  Visit 3 (reference = visit 1)0.46 (0.18)\*0.34 (0.24)0.59 (0.28)\*0.12 (0.34)0.52 (0.21)\*Menstrual domain Treatment time  Visit 2 (reference = visit 1)0.10 (0.18)0.21 (0.29)0.02 (0.24)0.26 (0.39)0.08 (0.20)  Visit 3 (reference = visit 1)0.19 (0.18)0.36 (0.27)0.04 (0.25)0.58 (0.41)0.11 (0.20)Emotions domain Treatment time  Visit 2 (reference = visit 1)0.07 (0.15)0.15 (0.21)0.01 (0.21)0.82 (0.33)\*0.04 (0.18)  Visit 3 (reference = visit 1)0.14 (0.15)0.30 (0.21)0.003 (0.21)0.43 (0.29)0.13 (0.18)Body hair domain Treatment time  Visit 2 (reference = visit 1)0.03 (0.14)0.18 (0.19)−0.08 (0.20)−0.34 (0.20)0.10 (0.17)  Visit 3 (reference = visit 1)0.02 (0.14)0.24 (0.18)−0.16 (0.21)−0.37 (0.21)0.10 (0.17)Acne & Hair loss domain Treatment time*p = 0.008p = 0.043p = 0.007*  Visit 2 (reference = visit 1)−0.51 (0.28)−0.10 (0.19)0.01 (0.20)−0.46 (0.18)\*−0.55 (0.35)  Visit 3 (reference = visit 1)0.45 (0.26)0.08 (0.19)0.33 (0.21)−0.28 (0.19)0.71 (0.32)\*Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). Once PCOS was diagnosed, patients started metformin treatment. Visit 2 was 2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th month of treatment). The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale*Abbreviations*: *PCOS* polycystic ovary syndrome, *HRQoL* Health related Quality of life, *SE* standard error\**p* \< 0.05

These statements as well as the references contained within them are to be disregarded as it was discovered that the patients included in the analyses did not receive the MMAS and thus, the analyses did not adjust for the MMAS scores (as was erroneously asserted in the original text).
